Literature DB >> 12086899

Incidence of Helicobacter pylori in operatively managed acute nonvariceal upper gastrointestinal bleeding.

C S Callicutt1, S W Behrman.   

Abstract

Helicobacter pylori is a known contributor to ulcerogenesis and nonvariceal acute upper gastrointestinal hemorrhage. Its incidence in operatively managed patients with upper gastrointestinal hemorrhage is ill defined. Patients undergoing surgery for upper gastrointestinal hemorrhage secondary to gastroduodenal ulceration between 1993 and 1998 at the University of Tennessee were retrospectively reviewed. Factors examined included age, nonsteroidal drug use, endoscopic intervention, urgency of operation, and H. pylori status confirmed by histologic examination. Forty-two patients had surgery with three excluded because of a lack of histologic evaluation. The site of bleeding was gastric in 23 and duodenal in 14. H. pylori infection was present in nine (39.1%) gastric and 11 (68.7%) duodenal ulcers. The incidence of H. pylori infection was reduced in those over 60 years of age (28.6%). Endoscopy was performed in all patients, but only two had biopsies for assessment of H. pylori. Operative morbidity was 17.9% and mortality was 5.1%. No patient had rebleeding following surgery. The incidence of H. pylori in this population is less than that reported in uncomplicated ulcer disease. Those older than 60 tended to be H. pylori negative. Endoscopic assessment for H. pylori was infrequent. Traditional indications for surgical intervention in ulcer hemorrhage should not be altered based on H. pylori status.

Entities:  

Mesh:

Year:  2001        PMID: 12086899     DOI: 10.1016/s1091-255x(01)80103-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  14 in total

1.  Epidemiology of upper gastrointestinal bleeding.

Authors:  D A Gilbert
Journal:  Gastrointest Endosc       Date:  1990 Sep-Oct       Impact factor: 9.427

2.  Edgar J. Poth Memorial Lecture. Is Helicobacter pylori a myth or the missing link?

Authors:  W H Schwesinger
Journal:  Am J Surg       Date:  1996-11       Impact factor: 2.565

3.  The national ASGE survey on upper gastrointestinal bleeding. I. Study design and baseline data.

Authors:  F E Silverstein; D A Gilbert; F J Tedesco; N K Buenger; J Persing
Journal:  Gastrointest Endosc       Date:  1981-05       Impact factor: 9.427

4.  Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.

Authors:  D Y Graham; G M Lew; P D Klein; D G Evans; D J Evans; Z A Saeed; H M Malaty
Journal:  Ann Intern Med       Date:  1992-05-01       Impact factor: 25.391

5.  Current peptic ulcer time trends. An epidemiological profile.

Authors:  J H Kurata; E D Corboy
Journal:  J Clin Gastroenterol       Date:  1988-06       Impact factor: 3.062

6.  Use of omeprazole in the management of giant duodenal ulcer: results of a prospective study.

Authors:  D R Fischer; M S Nussbaum; T A Pritts; N H Gilinsky; R E Weesner; S P Martin; R A Giannella
Journal:  Surgery       Date:  1999-10       Impact factor: 3.982

7.  Endoscopic hemostasis. An effective therapy for bleeding peptic ulcers.

Authors:  H S Sacks; T C Chalmers; A L Blum; J Berrier; D Pagano
Journal:  JAMA       Date:  1990-07-25       Impact factor: 56.272

8.  Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease.

Authors:  T Rokkas; A Karameris; A Mavrogeorgis; E Rallis; N Giannikos
Journal:  Gastrointest Endosc       Date:  1995-01       Impact factor: 9.427

9.  Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage.

Authors:  D Jaspersen; T Koerner; W Schorr; M Brennenstuhl; C Raschka; C H Hammar
Journal:  Gastrointest Endosc       Date:  1995-01       Impact factor: 9.427

10.  Density of Helicobacter pylori infection in patients with peptic ulcer perforation.

Authors:  Y Tokunaga; K Hata; J Ryo; A Kitaoka; A Tokuka; K Ohsumi
Journal:  J Am Coll Surg       Date:  1998-06       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.